国产吡非尼酮治疗特发性肺纤维化Ⅱ期临床研究被引量：20

Clinical Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

导出

摘要目的探讨吡非尼酮片治疗特发性肺纤维化(IPF)的临床疗效和安全性。方法采用多中心、随机、双盲、安慰剂对照的方法,筛选出87例IPF患者,所有受试者均经知情同意自愿参加。按照随机化数字方法分为两组:吡非尼酮组(A组,43例),口服国产吡非尼酮片,疗程48周,每次2片(0.4 g),每日3次(1.2 g/d),餐后服用;安慰剂组(B组,44例),口服安慰剂,疗程和用法同A组。观察时间为用药12、24、36和48周。观察指标包括:1临床疗效指标:肺功能变化,6分钟步行试验(6MWT),生活质量评分变化等;2安全性指标:不良事件发生率,以评价药物对IPF患者的临床有效性以及安全性。结果主要疗效指标变化:用药12周,A组用力肺活量(FVC)增加(90±410)m L,B组下降(70±310)m L,两组患者FVC变化值比较,差异有统计学意义(P<0.05)。次要疗效指标变化:(1)第1秒用力呼气容积(FEV1):用药12和24周,两组患者FEV1变化值比较,差异有统计学意义(P<0.05);(2)两组患者一氧化碳弥散量(DLCO):两组患者DLCO变化值比较,差异无统计学意义(P>0.05);(3)6MWT:用药36和48周,两组患者6MWT行走距离变化值比较,差异有统计学意义(P<0.05);(4)生活质量评分:在用药12(症状除外)、24、36及48周各个时间点与基线的评分变化,两组患者圣乔治呼吸问卷(SGRQ)评分以及呼吸困难评分之间的差异均有统计学意义(P<0.05)。安全性:A组43例患者中有36例发生不良事件,发生率为83.72%;B组44例患者中有32例发生不良事件,发生率为72.73%;发生率组间比较,差异无统计学意义(P>0.05)。结论国产吡非尼酮片治疗IPF具有良好的临床疗效和安全性。 Objective To evaluate the clinical efficacy and safety of pirfenidone in Chinese patients with idiopathic pulmonary fibrosis （IPF）. Methods In a multicenter, randomized, double-blind, comparative clinical trial, 87 patients with IPF were randomly divided into two groups. Group A （43 patients） were treated with pirfenidone （1 200 mg per day） for 48 weeks, while Group B （44 patients） were treated with placebo. Clinical features were compared between two groups including efficacy indicators （pulmonary function ,6MWT, and quality of life scores） and safety indicators （incidence of adverse events）. Results Forced vital capacity （FVC） was increased by （90 ± 410）mL in Group A and decreased by （70±310）mL in Group B （P 〈0. 05） ;In Group A,forced expiratory volume in 1 second was raised by （100 ± 330） mL and （110 ± 240 ）mL following 12 and 24 weeks after treatment, significantly different from group B （P 〈0.05）. There were significant differences in 6MWT between two groups 36 and 48 weeks after treatment respectively（ both P 〈 0. 05）. Quality of life scores, including the St. George＇ s score （ excluding symptoms） and dyspnea score,were significantly higher in Group A than Group B （both P 〈 0. 05 ）. There was no significant difference in the incidence of adverse events between Groups A and B （ 83.72% vs. 72. 73 % ,P 〉 O. 05）. Conclusion Domestic pirfenidone is clinically effective and safe for the treatment of IPF in Chinese patients.

作者李惠萍王思勤周建英万欢英王利民王广发银培基

机构地区同济大学附属上海市肺科医院河南省人民医院浙江大学医学院附属第一医院上海交通大学医学院附属瑞金医院杭州市第一人民医院北京大学第一医院南京正大天晴制药有限公司

出处《中国呼吸与危重监护杂志》 CAS 北大核心 2015年第3期229-235,共7页 Chinese Journal of Respiratory and Critical Care Medicine

关键词特发性肺纤维化吡非尼酮 Idiopathic pulmonary fibrosis Pirfenidone

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献13

1Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J,2010,35:496-504.
2Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo- controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med,2005 ,171:1040-1047.
3Pecci A, Biino G, Fierro T, et al. Alteration of liver enzymes is a feature of the MYH9-related disease syndrome. PLoS One,2012,7: e35986.
4King TE Jr, Bradford WZ, Castro-Bemardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med ,2014,370:2083-2092.
5Luppi F, Spagnalo P, Cerri S, et al. The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med,2012,18:428- 432.
6Liu Y. Hepatoeyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol, 2004,287 : F7-F16.
7Navarre-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, et al. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmaeo1,2012,678 : 71-77.
8Suga H, Teraoka S, Ota K, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol, 1995,47:287-291.
9Hisatomi K, Mukae H, Sakamoto N, et al. Pirfenidone inhibits TGF- betal-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med,2012,12:24.
10Shi Q, Liu X, Bai Y, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One, 2011,6 : e28134.